BOSTON, July 29, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, August 6, 2019 at 4:30 p.m. EDT to report its financial results for the quarter...
Author: brian@
Cidara Therapeutics Reports Positive Topline Results In Phase 2 STRIVE B Trial of Antifungal Rezafungin
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global Phase 2 STRIVE trial evaluating the company’s lead antifungal candidate rezafungin.
HHS, DoD, VenatoRx Pharmaceuticals to co-develop novel antibiotic to treat drug-resistant infections
WASHINGTON & MALVERN, Pa.–(BUSINESS WIRE)–The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will collaborate with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and VenatoRx Pharmaceuticals, Inc. of Malvern, Pennsylvania, to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available...
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
BOSTON, June 25, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the promotion of Evan Loh, M.D., to Chief Executive Officer, effective June 25, 2019. Dr. Loh will continue to serve on the Paratek Board of Directors. Michael Bigham, who has served as...
Entasis Therapeutics Appoints David Meek as Chairman of the Board
WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company…
VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia
Malvern, PA, June 20, 2019 – VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
VenatoRx Pharmaceuticals Joins Antimicrobials Working Group
WASHINGTON, Jan. 3, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of VenatoRx Pharmaceuticals, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 15 antimicrobial drug companies. VenatoRx is a world leader in antibacterial and antiviral drug...
Entasis Therapeutics Inc. Joins Antimicrobials Working Group
WASHINGTON D.C., July 2, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Entasis Therapeutics Inc. (Entasis) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Entasis utilizes a unique pathogen-targeted approach to develop a robust clinical and pre-clinical pipeline of potential first-...